Search
Nizubaglustat
go.drugbank.com/drugs/DB21603InvestigationalNizubaglustat has a monoisotopic molecular weight of 433.23 Da. … Nizubaglustat is a small molecule drug. The usage of the INN stem '-glustat' in the name indicates that Nizubaglustat is a ceramide glucosyltransferase inhibitor.
Synonyms: AZ-3102Trefentanil
go.drugbank.com/drugs/DB09181ExperimentalTrefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. It is more potent and shorter acting than alfentanil. … Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.
Irampanel
go.drugbank.com/drugs/DB21123InvestigationalIrampanel has a monoisotopic molecular weight of 309.15 Da. … Irampanel is a small molecule drug.
Salacetamide
go.drugbank.com/drugs/DB20217InvestigationalSalacetamide has a monoisotopic molecular weight of 179.06 Da. … Salacetamide is a small molecule drug.
Aftobetin
go.drugbank.com/drugs/DB20425InvestigationalAftobetin has a monoisotopic molecular weight of 452.23 Da. … Aftobetin is a small molecule drug.
Itruvone
go.drugbank.com/drugs/DB21543InvestigationalItruvone has a monoisotopic molecular weight of 296.21 Da. … Itruvone is a small molecule drug. Itruvone is under investigation in clinical trial NCT02322086 (A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10).
Azilsartan mopivabil
go.drugbank.com/drugs/DB21569ExperimentalAzilsartan mopivabil has a monoisotopic molecular weight of 676.25 Da. … Azilsartan mopivabil is a small molecule drug.
Taragarestrant
go.drugbank.com/drugs/DB21574InvestigationalTaragarestrant has a monoisotopic molecular weight of 474.13 Da. … Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).
Synonyms: D 0502Riselcaftor
go.drugbank.com/drugs/DB21685ExperimentalRiselcaftor has a monoisotopic molecular weight of 516.17 Da. … Riselcaftor is a small molecule drug.
Vayarin
go.drugbank.com/drugs/DB09328ApprovedA slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].